Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review

British Journal of Psychiatry

Volumn 168, Issue MAY SUPPL. 29, 1996, Pages 23-31

  Meltzer, Herbert Y ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPEROZIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; FLUPERLAPINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN RECEPTOR; THIORIDAZINE;

HUMAN; PSYCHOSIS; REVIEW; ANIMAL; BRAIN; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG EVALUATION, PRECLINICAL; HUMANS; RECEPTORS, SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 0029954801     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298280     Document Type: Review

References (91)

1. 2 receptors: an autoradiographic analysis in rat brain. Brain Research Bulletin, 16, 517-525.
2. ANDERSEN, P. H. & BRAESTRUP, C. (1986) Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. Journal of Neurochemistry, 47, 1822-1831.
3. 2 receptors in rat cerebral cortex. Journal of Neurochemistry, 46, 191-197.
4. ASHBY, C. R., JR, MINABE, Y., EDWARDS, I., et al (1991) Comparison of the effects of various typical and atypical antipsychotic drugs on the suppressant action of 2-methyl-serotonin on medial prefrontal cortical cells in the rat. Synapse, 8, 155-161.
5. BALSARA, J. J., JAELHAV, J. H. & CHANDORKAR, A. G. (1979) Effect of drugs influencing central serotonergic mechanisms or haloperidol-induced catalepsy. Psychopharmacology, 22, 67-69.
6. 2 receptor blocking agent. Current Therapeutic Research, 40, 492-499.
7. 3 receptors in rat striatum. Journal of Pharmacology and Experimental Therapeutics, 251, 803-809.
8. BORISON, R. L., DIAMOND, B. I., PATHIRAJA, A. P., et al (1992) Clinical overview of risperidone. In Novel Antipsychotic Drugs (ed. H. Y. Meltzer), pp. 233-239. New York: Raven Press,
9. BUNNEY, B. S., CHIODO, L. A. & GRACE, A. A. (1991) Midbrain dopamine system electrophysiological functioning: a review and hypothesis. Synapse, 9, 79-94.
10. 1C sites. European Journal of Pharmacology, 191, 93-96.
11. CHIODO, L. A. & BUNNEY, B. S. (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Journal of Neuroscience, 3, 1607-1619.
12. _ & _ (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. Journal of Neuroscience, 5, 2525-2544.
13. CHOUINARD, G., JONES, B., REMINGTON, G., et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25-40.
14. CORBETT, R., HARTMAN, H., KERMAN, L. L., et al (1993) Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacology, Biochemistry and Behavior, 45, 9-17.
15. COSTALL, B. & NAYLOR, R. J. (1973) Neuroleptic interactions with the serotonergic-dopaminergic mechanisms in the nucleus accumbens. Journal of Pharmacy and Pharmacology, 30, 257-259.
16. CREESE, I., BURT, D. R. & SNYDER, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science, 192, 481-483.
17. DALY, S. A. & WADDINGTON, J. L. (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology, 32, 509-510.
18. 2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. British Journal of Psychiatry, 163, 451-454.
19. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538-544.
20. GELDERS, Y. G., HEYLEN, S. L., VANDEN-BUSSCHE, G., et al (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry, 23, 205-211.
21. GOFF, D. C., MIDHA, K. K., BROTMAN, A. W., et al (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. Journal of Clinical Psychopharmacology, 11, 193-197.
22. GOLDSTEIN, J. M., LITWIN, L. C., SUTTON, E. B., et al (1989) Effects of ICI 169,369, a selective serotonin antagonist in electrophysiological tests predictive of antipsychotic activity. Journal of Pharmacology and Experimental Therapeutics, 249, 673-680.
23. _, _, _, et al (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology, 112, 293-298.
24. 2 receptor indices in clozapine treated schizophrenic patients. Schizophrenia Research, 9, 199.
25. HICKS, P. B. (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sciences, 47, 1609-1615.
26. 2 receptors. Journal of Pharmacology and Experimental Therapeutics, 263, 276-284.
27. ICHIKAWA, J. & MELTZER, H. Y. (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics, 256, 348-357.
28. IMPERATO, A. & ANGELUCCI, L. (1989) The effect of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the frontal cortex of freely-moving rats. Psychopharmacology Bulletin, 25, 383-389.
29. KAHN, R. S., SIEVER, L., DAVIDSON, M., et al (1993) Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology, 112 (suppl.), S90-S94.
30. KANE, J., HONIGFELD, G., SINGER, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
31. KORSGAARD, S., GERLACH, J. & CHRISTENSSON, E. (1985) Behavioral aspects of serotonin-dopamine interactions in the monkey. European Journal of Pharmacology, 118, 245-252.
32. KRUPP, P. & BARNES, P. (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology, 99 (suppl.), S118-S121.
33. 1C receptor density in the rat choroid plexus: comparison with haloperidol. Journal of Pharmacology and Experimental Therapeutics, 264, 1262-1267.
34. 2) receptor numbers in the rat brain. Psychiatry Research, 12, 277-285.
35. LEYSEN, J. E., GOMMEREN, W., EENS, A., et al (1988) Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics, 247, 661-670.
36. 2 receptors. Psychopharmacology, 112 (suppl.), S40-S54.
37. 1A receptors in human brain tissue. European Journal of Pharmacology, 221, 397-398.
38. 2 receptor density in rat cerebral cortex. Life Sciences, 45, 1397-1406.
39. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. Journal of Pharmacology and Experimental Therapeutics, 265, 498-508.
40. MATTHYSSHE, S. (1974) Dopamine and the pharmacology of schizophrenia: the state of the evidence. Journal of Psychiatry Research, 11, 107-113.
41. MEGENS, A. A. H. P., AWOUTERS, F. H. L., SCHOTTE, A., et al (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology, 114, 9-23.
42. MELTZER, H. Y. (1988) Clozapine: clinical advantages and biological mechanisms. In Schizophrenia: A Scientific Focus (eds S. C. Schulz & C. A. Tamminga), pp. 302-309. New York: Oxford University Press.
43. _ (1990) Clozapine: mechanism of action in relation to its clinical advantages. In Recent Advances in Schizophrenia (eds A. Kales, G. N. Stefanos & J. A. Talbott), pp. 237-246. Heidelberg: Springer-Verlag.
44. _ (1991a) Dopaminergic and serotonergic mechanisms in the action of clozapine. In Advances in Neuropsychiatry and Psychopharmacology. Vol. 1: Schizophrenia Research (eds S. C. Schulz & C. A. Tamminga), pp. 333-340. New York: Raven Press.
45. _ (1991b) The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin, 17, 263-287.
46. _ (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin, 18, 515-542.
47. _ (1995) The concept of atypical antipsychotics. In Advances in the Neurobiology of Schizophrenia (eds J. A. den Boer, H. G. M. Westenberg & H. M. van Pragg), pp. 265-273. Chichester: Wiley.
48. 2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 252, 238-246.
49. _ & NASH, J. F. (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacology Reviews, 43, 587-604.
50. 2 receptor occupancy: implications for antipsychotic action. European Journal of Pharmacology, 216, 67-71.
51. _, MAES, M. & LEE, M. A. (1993) The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Psychopharmacology, 112 (suppl.), S95-S104.
52. _, CHAI, B. L., THOMPSON, P. A., et al (1994) Effect of scopolamine on the efflux of dopamine and its metabolites following clozapine, haloperidol or thioridazine. Journal of Pharmacology and Experimental Therapeutics, 268, 1452-1461.
53. _, YAMAMOTO, B. K., LOWY, M. T., et al (1995) The mechanism of action of atypical antipsychotic drugs: an update. In Biology of Schizophrenia and Affective Disease- ARNMD Series (eds S. J. Watson & H. Akil), pp. 451-492. New York: Raven Press.
54. MIGLER, B. M., WARAWA, E. J. & MALIK, J. B. (1993) Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology, 112, 299-307.
55. 1A agonists, S14506 and S14671. Neuroscience Abstracts, 19, 597.
56. MOGHADDAM, B. & BUNNEY, B. S. (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. Journal of Neurochemistry, 54, 1775-1760.
57. 1C receptor in a prominent serotonin receptor subtype in the central nervous system. Proceedings of the National Academy of Science, USA, 89, 6793-6797.
58. MONSMA, F. J., JR, SHEN, Y., WARD, R. R., et al (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molecular Pharmacology, 43, 320-327.
59. NASH, J. F. (1990) Ketanserin pretreatment attenuates NDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sciences, 47, 2402-2408
60. NEAL-BELIVEAU, B. S., JOYCE, J. N. & LUCKI, I. (1993) Serotonergic involvement in haloperidol-induced catalepsy. Journal of Pharmacology and Experimental Therapeutics, 265, 207-217.
61. O'DELL, S., LA HOSTE, G. J., WIDWARK, C. B., et al (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serontonin receptor in rat brain. Synapse, 6, 146-153.
62. OWENS, R. R., JR, GUTIERREZ-ESTEINOU, R., HSAIO, J., et al (1993) Effect of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Archives of General Psychiatry, 50, 636-644.
63. PEHEK, E. A., YAMAMOTO, B. K. & MELTZER, H. Y. (1991) The effects of clozapine on dopamine, 5-HT and glutamate release in the rat medial prefrontal cortex. Schizophrenia Research, 4, 324.
64. RAO, T. S., CONTRERAS, P. C., CLER, J. A., et al (1991) Clozapine attenuates n-methyl-D-aspartate receptor complex-mediated responses in vivo: tentative evidence for a functional modulation by a noradrenergic mechanism. Neuropharmacology, 30, 557-565.
65. 3 receptors in vitro and in vivo. Neuroscience Abstracts, 10, 597.
66. ROGUE, A. &. ROGUE, P. (1992) Mianserin in the management of schizophrenia. Schizophrenia 1992, International Conference Abstract Book, p. 125. Vancouver, British Columbia.
67. 1C receptors. Journal of Pharmacology and Experimental Therapeutics, 260, 1361-1365.
68. 7 receptors. Journal of Pharmacology and Experimental Therapeutics, 268, 1406-1410.
69. SALLER, C. F. & SALAMA, A. I. (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology, 112, 285-292.
70. 2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. Journal of Pharmacology and Experimental Therapeutics, 255, 478-483.
71. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine. European Journal of Pharmacology, 223, 65-74.
72. 2 receptors exert a state dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. European Journal of Pharmacology, 223, 65-74.
73. SCHOTTE, AS., DE BRUYCKERE, K., JANSSEN, P. F., et al (1989) Receptor occupancy by ritanserin and risperidone measured using ex vivo radiography. Brain Research, 500, 295-301.
74. SEEMAN, P. & LEE, T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science, 188, 1217-1219.
75. SHEN, Y., MONSMA, F. J., JR, METCALF, M. A., et al (1993) Molecular cloning and expression of a 5-hydroxytryptamine serotonin receptor subtype. Journal of Biology and Chemistry, 268, 18200-18204.
76. SKARSFELDT, T. & PERREGARD, J. (1990) Sertindole, a new neuroleptic with extreme selectivity on AlO versus A9 dopamine neurons in the rat. European Journal of Pharmacology, 182, 613-614.
77. 2 antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. Journal of Pharmacology and Experimental Therapeutics, 260, 872-878.
78. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. Journal of Pharmacology and Experimental Therapeutics, 266, 684-691.
79. STOCKMEIER, C. A., DICARLO, J. J., ZHANG, Y., et al (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy serotonin-2 and dopamine-2 receptors. Journal of Pharmacology and Experimental Therapeutics, 266, 1374-1384.
80. 2 receptor occupancy rates by haloperidol and clozapine in vivo. Japanese Journal of Psychiatry and Neurology, 47, 131-137.
81. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology, 98, 45-50.
82. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614.
83. 3 receptors. European Journal of Pharmacology, 213, 2163-2164.
84. WADENBERG, M. L., AHLEWNIUS, S. & SVENSSON, T. H. (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonist: implications for the mechanism of action of clozapine. Psychopharmacology, 110, 273-279.
85. 2 receptors of normal human brain in vitro. European Journal of Pharmacology, 143, 279-282.
86. 3 receptors in the cerebral cortex and superior cervical ganglion of the rat. European Journal of Pharmacology, 182, 465-472.
87. WHITE, F. J. & WANG, R. Y. (1983) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sciences, 32, 983-993.
88. WIESEL, F. A,. NORDSTRÖM, A.-L., FARDE, L., et al (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology, 114, 31-38.
89. WILEY, J. L. & PORTER, J. H. (1992) Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacology, Biochemistry and Behavior, 43, 961-965.
90. 2) receptors in the rat brain. Brain Research, 487, 288-298.
91. YAMAMOTO, B. K. & COOPERMAN, M. A. (1992) Effect of chronic antipsychotic treatment of extracellular dopamine and glutamate concentrations in the rat striatum. Society of Neuroscience Abstracts, 18, 379.